
Are you ready?

Vaccine recommendations and
coming attractions

The logo for the Oregon Health Authority is centered within a light blue, curved banner. It features the word "Oregon" in orange, "Health" in blue, and "Authority" in orange, all in a serif font. A thin blue horizontal line is positioned below the word "Health".

Oregon
Health
Authority

COVID

again. . . still?

Primary Series

Updated Recommendations

- Unvaccinated (immunocompetent)
 - people ≥ 6 years = 1 bivalent dose
 - 5 year-olds, depends
 - Moderna = 2 bivalent doses
 - Pfizer = 1 bivalent dose
 - ≥ 6 months through 4 years, depends
 - Moderna = 2 bivalent doses
 - Pfizer = 3 doses

Primary Series

Updated Recommendations

- Unvaccinated (immunocompromised)
 - 3 bivalent doses

Previously Vaccinated Updated Recommendations

- Immunocompetent
 - Use your resources!
 - [Interim Clinical Considerations](#)
 - [Model Immunization Protocol](#)
- Immunocompromised
 - Have they already received a bivalent dose?
 - Has it been at least 2 months since the last dose?
 - [CDC guidance](#)

Table 2. Recommended COVID-19 vaccination schedule for people who are moderately or severely immunocompromised by COVID-19 vaccination history, May 2023

mRNA COVID-19 vaccines

Ages 6 months–4 years

COVID-19 vaccination history	Bivalent vaccine	Number of bivalent doses indicated*	Dosage (mL/ug)	Vaccine vial cap and label colors	Interval between doses
Unvaccinated	Moderna — <i>or</i> — Pfizer BioNTech†	3	0.25 mL/25 ug	Blue cap; gray label border	Dose 1 and Dose 2: 4 weeks Dose 2 and Dose 3: At least 4 weeks
		3	0.2 mL/3 ug	Maroon	Dose 1 and Dose 2: 3 weeks Dose 2 and dose 3: At least 8 weeks
1 dose monovalent Moderna	Moderna	2	0.25 mL/25 ug	Blue cap; gray label border	Dose 1: 4 weeks after monovalent dose Dose 1 and Dose 2: At least 4 weeks
2 doses monovalent Moderna	Moderna	1	0.25 mL/25 ug	Blue cap; gray label border	At least 4 weeks after last monovalent dose
3 doses monovalent Moderna	Moderna	1	0.2 mL/10 ug	Dark pink cap; yellow label border	At least 8 weeks after last monovalent dose
3 doses monovalent Moderna and 1 dose bivalent Moderna	—	See footnote	—	—	—
1 dose monovalent Pfizer-BioNTech	Pfizer- BioNTech†	2	0.2 mL/3 ug	Maroon	Dose 1: 3 weeks after monovalent dose Dose 1 and Dose 2: At least 8 weeks

Booster Doses

- Adults ≥ 65 years of age
 - May opt to receive a single bivalent dose
 - Spacing of 4 or more months since last dose
- Persons who are immunocompromised
 - May receive one or more additional bivalent doses in consultation with their healthcare provider
 - Spacing of 2 or more months since last dose

COVID Vaccine Commercialization

What, When, How, etc.

- COVID vaccines (and therapeutics) will shift to commercial distribution like other vaccines
- Will be included in VFC
- Anticipated timeline is fall of 2023
- FDA's VRBAC Committee will be meeting in June to discuss strain selection
- Federal Government is creating a new “bridge” program for uninsured adults through pharmacies and public health clinics

RSV Vaccines and monoclonal antibodies

Arexvy[®] by GSK

- First licensed vaccine for RSV
- For adults ≥ 60 years of age
- One 0.5 mL dose given IM
- Lyophilized vaccine with adjuvant diluent



RSV Vaccine Candidate by Pfizer

- Phase 3 trials complete
 - Adults \geq 60 years of age
 - Pregnant women in the late 2nd to 3rd trimester
 - Safety was assessed in women for 6 months post-delivery
 - Infants were followed for at least 1 year for safety and efficacy

Nirsevimab by AstraZeneca and Sanofi

- Long-acting antibody
- Single dose for healthy infants
 - Before hospital discharge for infants born in the fall/winter
 - At a clinic visit for infants born in spring/summer
- A 2nd dose can be given to high-risk infants at the beginning of their 2nd RSV season

Coming Attractions

- VRBAC – meeting June 15th
 - Discussion of COVID-19 strains for the 2023-24 fall/winter vaccination campaign
- ACIP – meeting June 21-23
 - Votes
 - RSV for adults
 - Polio for adults
 - Influenza
 - Pneumococcal for children

Discussion

Amanda Timmons

Immunization Policy Analyst

amanda.j.timmons@oha.oregon.gov

503-269-3288